Compare SAMG & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAMG | XBIT |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4M | 70.1M |
| IPO Year | 2012 | 2015 |
| Metric | SAMG | XBIT |
|---|---|---|
| Price | $10.18 | $2.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 56.4K | 45.0K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $91,358,000.00 | N/A |
| Revenue This Year | $8.99 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $203.40 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.57 | $2.09 |
| 52 Week High | $16.56 | $3.44 |
| Indicator | SAMG | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 40.99 |
| Support Level | $9.69 | $2.21 |
| Resistance Level | $10.63 | $2.46 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 46.46 | 11.76 |
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income, and cash, as well as non-traditional investment strategies including hedge funds, private equity funds, real estate, and commodities. The firm offers a full suite of complementary and customized family office services for families seeking comprehensive oversight of their financial affairs. The company derives revenues from Managed accounts, Silvercrest funds, Tax and family office services, and Fund administration. The firm generates the majority of its revenue from Managed Accounts.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.